Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coal tar-less Denorex

This article was originally published in The Tan Sheet

Executive Summary

Reformulations of regular, extra strength dandruff shampoos expected to reach store shelves by mid-December, Whitehall-Robins says. Firm replaced active ingredient coal tar with salicylic acid under final terms of Prop 65 settlement in California. Settlement also required Whitehall to pay $427,500 penalty (1"The Tan Sheet" Sept. 10, In Brief)...

You may also be interested in...



Prop 65 and coal tar

California AG seeking new trial date against Tegrin dandruff shampoo marketer Reedco following settlements by other defendants in Prop 65 litigation. Under agreements not yet filed in San Francisco state court, settling defendants - including J&J's Neutrogena division, distributor Bergen Brunswig - would have to place Prop 65 warning on all coal tar-containing creams, as well as shampoos exceeding .5% coal tar equivalent. January trial date was vacated in light of settlements; remaining defendant Reedco is subsidiary of GlaxoSmithKline's Block Drug. Whitehall-Robins previously agreed to reformulateDenorex, pay $427,500 to settle the litigation (1"The Tan Sheet" Nov. 19, 2001, In Brief)...

Prop 65

Whitehall-Robins to reduce level of coal tar in Denorex dandruff shampoo by 72%, pay $427,500 penalty under settlement with Occupational Knowledge International. Settlement requires lower coal tar formulation by year-end. Twenty other manufacturers of coal tar shampoos and related products named in suit, including J&J (Neutrogena) and Reedco (Tegrin), have yet to settle (1"The Tan Sheet" March 26, p. 21). Case is scheduled to go to trial in January

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel